Recurrence rate of hirsutism after 3 different antiandrogen therapies.
BACKGROUND
Although antiandrogens are frequently and successfully used to treat hirsutism, little attention has been paid to optimal duration of treatment and recurrence rate after cessation of therapy.


OBJECTIVE
Our purpose was to determine the recurrence rate of hirsutism after 3 different antiandrogen therapies.


METHODS
Eighty-one hirsute women referred to a tertiary hirsutism clinic were assigned to one of three regimens: spironolactone 100 mg/day with an oral contraceptive, cyproterone acetate 50 mg/day on days 1 to 10 with an oral contraceptive, or flutamide 250 mg twice a day. Hirsutism scores according to the Ferriman-Gallwey scoring system and endocrine parameters were evaluated before, during, and 1 year after withdrawal of treatment regimens.


RESULTS
Hirsutism scores decreased significantly and similarly in spironolactone, flutamide, and cyproterone acetate treatment groups. However, 1 year after withdrawal of treatment in all antiandrogen therapy groups, hirsutism returned.


CONCLUSIONS
Antiandrogens are effective in the treatment of hirsutism. However, cessation of antiandrogen therapy is followed by recurrence.
Yücelten
D
D
Department of Dermatology, Marmara University School of Medicine, Istanbul, Turkey.
Erenus
M
M
Gürbüz
O
O
Durmuşoğlu
F
F
D000726:Androgen Antagonists / Q000627:therapeutic use*; D003276:Contraceptives, Oral / Q000627:therapeutic use; D003534:Cyproterone / Q000627:therapeutic use; D005260:Female; D005485:Flutamide / Q000627:therapeutic use; D006628:Hirsutism / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood; D012008:Recurrence; D013148:Spironolactone / Q000627:therapeutic use; D013739:Testosterone / Q000097:blood
D000726:Androgen Antagonists; D003276:Contraceptives, Oral; D013148:Spironolactone; D013739:Testosterone; D005485:Flutamide; D007986:Luteinizing Hormone; D003534:Cyproterone